CELLIVITY is available to adults only. Supplement pages are general product information; peptide records are not a sales offer and are not for human use.
Age confirmation is a declaration, not identity verification. Restricted research access still requires separate professional eligibility checks.Privacy and legal notice ↗
Open full-size image ↗Packaging concept; the selected format is shown below.Selected format: 15 mg
This image is a CELLIVITY packaging concept. Current stock arrived in clear vials without individual labels; product details are on the outer box of 10 vials. Packaging for your selected quantity will be confirmed when you enquire.
CELLIVITY PEPTIDE LABS · CEL-P-BPC-001
BPC-157
Lyophilised research-vial concept
For laboratory research only · Not intended for human or veterinary use.
THAILAND LAUNCH PRICE฿2,25015 mg · per vial · tax and delivery confirmed at enquiry
Received · batch documentation under reviewAvailability is confirmed for this exact format before any commitment.
BPC-157 is a synthetic 15-amino-acid research peptide associated with a fragment described from gastric proteins. Most discussion around repair comes from laboratory and animal models, not from reliable controlled human trials.
Research focus
Preclinical tissue-response, inflammation and injury-model research.
Current evidence context
Preclinical signals do not establish a recovery treatment. Reliable controlled human efficacy evidence is absent, while product-related impurities, aggregation and route-dependent immunogenicity remain material uncertainties.
Questions this record follows
Can exact sequence and salt form be confirmed across supplier lots?
Which tissue-response findings reproduce in independent preclinical models?
What human pharmacology, safety and immunogenicity data are still missing?
Follow the sources
Registry entries identify reference substances. Literature links describe research and do not certify this product or its batch.
Request current availability for a lawful institutional, analytical or laboratory purpose. We confirm the exact presentation, price, batch and document state before any next step.
Exact presentation review
Jurisdiction and purpose check
Batch-document confirmation
No medical or human-use guidance
SELECTED PRODUCTBPC-157CEL-P-BPC-001 · response after manual review
BPC-157: before you enquire
What exactly does the selected format mean?＋
The mg or IU value is the declared material content per vial; it is not the container volume. Your selected presentation and quantity are saved with your enquiry. The final price is confirmed in the response.
Which batch will be supplied?＋
The specific batch and its documents are confirmed in the response. Files shown here may be supplier reference samples; the current record does not yet contain a qualified CELLIVITY lot dossier.
When can it arrive in Thailand?＋
For confirmed local stock, the planned window is 2–3 working days in Thailand. Pattaya timing is agreed directly. Incoming or specially sourced products have a separate estimate, confirmed before a commitment.
Can I enquire about several products together?＋
Yes. Add each format and quantity to the cart, then send one availability enquiry. Your selected items are kept together for review.
CELLIVITY
BPC-157
CEL-P-BPC-001 · 5 mg / 10 mg / 15 mg
BPC-157 is a synthetic 15-amino-acid research peptide associated with a fragment described from gastric proteins. Most discussion around repair comes from laboratory and animal models, not from reliable controlled human trials.
Preclinical tissue-response, inflammation and injury-model research.
Other names
BPC 157 · BPC 15 · Bepecin
PubChem CID
9941957
CAS number
137525-51-0
Molecular formula
C62H98N16O22
Molecular weight
1419.5 g/mol
Peptide length
15 amino acids
Compound class
Synthetic linear pentadecapeptide
Follow the sources
Preclinical signals do not establish a recovery treatment. Reliable controlled human efficacy evidence is absent, while product-related impurities, aggregation and route-dependent immunogenicity remain material uncertainties.
Can exact sequence and salt form be confirmed across supplier lots?
Which tissue-response findings reproduce in independent preclinical models?
What human pharmacology, safety and immunogenicity data are still missing?
